Try our beta test site

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01639508
First received: July 10, 2012
Last updated: February 13, 2017
Last verified: February 2017